Evolent Health
EVH
232 hedge funds and large institutions have $2.76B invested in Evolent Health in 2022 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 86 increasing their positions, 85 reducing their positions, and 49 closing their positions.
81% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $6.4M
1% more repeat investments, than reductions
Existing positions increased: 86 | Existing positions reduced: 85
4.22% less ownership
Funds ownership: 103.93% → 99.71% (-4.2%)
8% less funds holding
Funds holding: 251 → 232 (-19)
18% less capital invested
Capital invested by funds: $3.35B → $2.76B (-$589M)
20% less funds holding in top 10
Funds holding in top 10: 10 → 8 (-2)
31% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$48.3M |
| 2 |
Holocene Advisors
New York
|
+$44.8M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$42.7M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.5M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$26.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$23.1M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
-$20.4M |
| 3 |
FAM
Fred Alger Management
New York
|
-$18.5M |
| 4 |
JP Morgan Chase
New York
|
-$14M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$13.5M |
EVH Hedge Fund Activity: Q4 2022 in Review
232 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q4 2022, worth a combined $2.76B — down 18% from $3.35B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of EVH and 34 opened new positions — a net loss of 15 holders — while 85 trimmed existing stakes and 86 added.
The largest buyer was Eventide Asset Management, adding an estimated $48.3M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $23.1M sold.
- 232 institutional investors held Evolent Health (EVH) as of Q4 2022, down from 251 in Q3 2022.
- Funds reported $2.76B of Evolent Health stock for Q4 2022, down 18% quarter-over-quarter.
- 34 funds opened new Evolent Health positions in Q4 2022 and 49 closed out, a net change of -15 holders.
- The largest Evolent Health buyer in Q4 2022 was Eventide Asset Management, an estimated $48.3M added.
- The largest Evolent Health seller in Q4 2022 was Lord, Abbett & Co, an estimated $23.1M sold.
Based on aggregated 13F filings for Q4 2022.